Printer Friendly

FUJISAWA USA SELLS PUERTO RICO PLANT TO CHIRON CORPORATION

 CHICAGO, Feb. 22 /PRNewswire/ -- Fujisawa USA, Inc., today announced the sale of its pharmaceutical filling and finishing facility in Canovanas, Puerto Rico to Chiron Corporation (NASDAQ-NMS: CHIR) for approximately $17 million. Fujisawa has two other manufacturing facilities in Melrose Park, Ill. and Grand Island, New York.
 Our recent investment of $9 million in upgrades and new systems for our mainland plants has enabled us to increase our manufacturing efficiency,'' said
Theron Odlaug, Ph.D., executive vice president, operations, Fujisawa USA. We are committed to continuous improvement, both in equipment and in employee training. As we bring new products on line, we will review our capacity needs and make decisions about how best to accommodate our growth.''
 The consolidation of our manufacturing activity in our U.S. mainland plants will help us better serve our customers by increased utilization of these facilities. Our customers will benefit from greater availability of product, as well as an efficient cost structure,'' said Patrick Walsh, vice
president, sales and marketing. We anticipate significant growth of our business over the next five years, and our existing facilities are well equipped to handled this planned growth.''
 Fujisawa USA, based in Deerfield, Ill., is a subsidiary of Fujisawa Pharmaceutical Ltd., a research-based manufacturer of proprietary and multi-source pharmaceutical products in Osaka, Japan.
 -0- 2/22/93
 /CONTACT: Gary Schmidt, 708-317-8916, or Paula Waters, 312-329-7532, both for Fujisawa USA/
 (CHIR)


CO: Fujisawa USA, Inc; Chiron Corporation ST: Illinois IN: MTC SU:

TM -- NY089 -- 9141 02/22/93 18:39 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 22, 1993
Words:251
Previous Article:WILLIE NELSON LAUNCHES FARM AID VI IN IOWA
Next Article:NEW YORK STOCK EXCHANGE CLOSING, MONDAY, FEB. 22 /PRN/
Topics:


Related Articles
FUJISAWA ANNOUNCES REORGANIZATION AND SENIOR EXECUTIVE APPOINTMENTS
FUJISAWA SUBMITS NEW DRUG APPLICATIONS TO FDA FOR FK-506
FUJISAWA USA PREPARES FOR ADENOSCAN(R) APPROVAL, PURSUES COMPLAINT AGAINST MEDCO RESEARCH AND ABBOTT
FUJISAWA USA TO MANUFACTURE KEY PRODUCT AT NEW CEPHALOSPORIN PLANT
FUJISAWA USA, INC. APPOINTS NEW CEO
Fujisawa Completes Tacrolimus (Fk506) Ointment Plant
Josette Wys Joins Inyx as Vice President Business Development.
Pfizer to Sell Fajardo Manufacturing Facility to Galen Holdings PLC.
Abbott Laboratories to Build Biotechnology Manufacturing Plant in Puerto Rico.
Pharmaceutical industry remains strong.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters